ArticlePloS one2026
Polylactic co-glycolic acid (PLGA)-based nanoparticles encapsulating Persea americana seed extract: A potential therapeutic strategy against oxidative stress and diabetes in rat model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia arising from insulin resistance or impaired insulin secretion. Conventional and commercially available effective antidiabetic drugs are often associated with adverse effects and reduced efficacy over prolonged use, highlighting the need for safer and plant-based alternatives. Persea americana seed extract (PSE) has antidiabetic potential but suffers from non-specific distribution and poor bioavailability, thus limiting its clinical application. This study developed and evaluated the poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating Persea americana seed extract (PSENP) to enhance therapeutic efficacy and delivery. Nanoparticles were characterized for zeta size, zeta potential, transmission electron microscopy (TEM), stability and their phytochemical composition, with HPLC confirming the presence of bioactive compounds including quercetin, syringic acid, and gallic acid. In-vivo, forty wistar rats were allocated into five groups: normal control, diabetic control, metformin-treated, PSE-treated, and PSENP-treated. Biochemical parameters were evaluated including fasting blood glucose, insulin (serum level), lipid profile, oxidative stress biomarkers (superoxide dismutase, catalase), and inflammatory cytokines (IL-6, TNF-α). Histopathological examination of pancreatic tissue and safety evaluations for kidney and liver were performed. Moreover, In-silico study demonstrated the strong binding affinity between quercetin and α-glucosidase, thus supporting the glucose-lowering role of quercetin. The PSENP administration resulted in statistically significant glycemic control, enhanced antioxidant activity of enzymes, improved lipid profile, reduced pro-inflammatory cytokines, and preservation of architecture of pancreas, with no renal and hepatic toxicity. The findings of the study indicated that PLGA-based nanoformulation of P. americana seed extract provides a promising therapeutic strategy for diabetes management and its oxidative and inflammatory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.